Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Oncogene - 9 Jun 2011

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A

Abstract excerpt

The tumor suppressor gene von Hippel-Lindau (VHL) is involved in the development of sporadic clear-cell renal cell carcinoma (RCC). VHL interferes with angiogenesis and also controls cell adhesion and invasion. Therapies that target VHL-controlled genes are currently being evaluated in RCC patients. RCC is a immunogenic tumor and treatment with interleukin-2 (IL2) or interferon (IFN)-α results in regression in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Cell Hypoxia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Kidney Neoplasms

Share to NK Cell Lectin-Like Receptor Subfamily C

Share to Vascular Endothelial Growth Factor A

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Identifiers

PMID: 21258414
DOI: 10.1038/onc.2010.638

Genes

VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.PMID 21258414Read ↗

Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinomaSemantic proximity Read ↗

VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.Semantic proximity Read ↗

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

A clearer view of the molecular complexity of clear cell renal cell carcinoma.Semantic proximity Read ↗

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.Semantic proximity Read ↗

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinomaSemantic proximity Read ↗

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells.Semantic proximity Read ↗

Molecular biology of renal cell carcinoma.Semantic proximity Read ↗

Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinomaSemantic proximity Read ↗

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.Semantic proximity Read ↗

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesisSemantic proximity Read ↗

Treatment of kidney cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.